Form 4 Passage Bio Inc For: 22 July
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Passage Bio Inc (PASG)
Track today's live Passage Bio (PASG) share price, performance and key data on this page with our current NASDAQ:PASG stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Passage Bio share price on the NASDAQ exchange. Use the dropdown to switch exchange for the PASG share price, head to our technical summary section, which provides analysis on Passage Bio share price buy/sell indicators using real-time data (or discuss the Passage Bio (PASG) stock price today with other investors in the Passage Bio NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:PASG share price (ISIN: US7027122099) to enhance your trading decisions with our free investment tools and resources.
What Is the Passage Bio Inc Share Price Today?
The Passage Bio share price today is 4.7500.
What Is the Stock Symbol for Passage Bio Inc
The stock symbol (or 'ticker') for Passage Bio Inc is "PASG."
What Stock Exchange Does Passage Bio Inc Trade On?
Passage Bio Inc is listed and trades on the NASDAQ stock exchange.
Is Passage Bio Inc a Good Stock to Buy?
Determining whether Passage Bio (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:PASG share price (ISIN: US7027122099) to enhance your trading decisions with our free investment tools and resources.
What Is the Passage Bio Inc Share Price Today?
The Passage Bio share price today is 4.7500.
What Is the Stock Symbol for Passage Bio Inc
The stock symbol (or 'ticker') for Passage Bio Inc is "PASG."
What Stock Exchange Does Passage Bio Inc Trade On?
Passage Bio Inc is listed and trades on the NASDAQ stock exchange.
Is Passage Bio Inc a Good Stock to Buy?
Determining whether Passage Bio (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.6600
4.9350
52 wk Range
3.2900
20.0000
PASG is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.66004.9350
52 wk Range
3.290020.0000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PASG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
15.5000
Upside
+226.32%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 10Q Passage Bio Inc For: 12 May- Investing.com
- Form 4 Passage Bio Inc For: 22 July
- Investing.com
Passage Bio Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
2 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 15.5000
(+226.32% Upside)
Earnings
Latest Release
30/07/2026
EPS / Forecast
-2.44 / -2.65
Revenue / Forecast
-- / --
Compare PASG to Peers and Sector
Metrics to compare | PASG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPASGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −2.4x | −0.4x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price/Book | 3.4x | 3.5x | 2.6x | |
Price / LTM Sales | - | 35.2x | 3.0x | |
Upside (Analyst Target) | 226.3% | 142.4% | 54.5% | |
Fair Value Upside | Unlock | 2.7% | 7.2% | Unlock |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Passage Bio (NASDAQ: PASG) Share Price Today?
The Passage Bio stock price today is 4.7500 USD.
What Stock Exchange Does Passage Bio (PASG) Trade On?
Passage Bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Passage Bio?
The stock symbol (also called a 'ticker') for Passage Bio is "PASG."
What Is the Current Passage Bio Market Capitalisation?
As of today, Passage Bio (NASDAQ: PASG) market cap is 15.2800M USD.
What Is Passage Bio's (PASG) Earnings Per Share (TTM)?
The Passage Bio EPS is currently -11.3086 (Trailing Twelve Months).
When Is the Next Passage Bio Earnings Date?
Passage Bio's next earnings report will be released on 16/11/2026.
Is PASG a Buy or Sell From a Technical Analyst Perspective?
Based on today's Passage Bio moving averages and other technical indicators, the daily buy/sell signal for PASG stock is Strong Sell.
How Many Times Has Passage Bio Stock Split?
Passage Bio has split 1 times. (See the PASG stock split history page for full effective split date and price information.)
How Many Employees Does Passage Bio Have?
Passage Bio has 24 employees, based on their latest Companies House report.
What is the current trading status of Passage Bio (NASDAQ: PASG)?
As of 20/09/2026, Passage Bio (PASG) is trading at a share price of 4.7500 USD, with a previous close of 4.7500 USD. The stock has fluctuated within a day range of 4.6600 USD to 4.9350 USD, while its 52-week range spans from 3.2900 USD to 20.0000 USD.
What Is Passage Bio (PASG) Price Target According to Analysts?
The average 12-month price target for Passage Bio is 15.5000 USD, with a high estimate of 23 USD and a low estimate of 8 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +226.32% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.